Levels of Circulating Progenitor Cells, Cardiovascular Outcomes and Death: A Meta-Analysis of Prospective Observational Studies

Circulation Research

Volumn 118, Issue 12, 2016, Pages 1930-1939

  Rigato, Mauro ^a   Avogaro, Angelo ^a   Fadini, Gian Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

endothelial progenitor cells; epidemiology; prevention control; regeneration; stem cells

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIRCULATING PROGENITOR CELL; COLONY FORMING CELL; CORONARY ANGIOGRAPHY; ENDOTHELIAL PROGENITOR CELL; FOLLOW UP; GENETIC HETEROGENEITY; HUMAN; LONGITUDINAL STUDY; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RESTENOSIS; REVASCULARIZATION; STEM CELL; BLOOD; GENETICS; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY;

AC133 ANTIGEN; ANTIGENS, CD34; BIOMARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIAL PROGENITOR CELLS; HUMANS; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84963978864     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308366     Document Type: Article

References (49)

1. Xanthakis V, Sullivan LM, Vasan RS, Benjamin EJ, Massaro JM, D'Agostino RB Sr, Pencina MJ. Assessing the incremental predictive performance of novel biomarkers over standard predictors. Stat Med. 2014;33:2577-2584. doi: 10.1002/sim.6165.
2. Naghavi M, Falk E, Hecht HS, et al; SHAPE Task Force. From vulnerable plaque to vulnerable patient-Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98:2H-15H. doi: 10.1016/j.amjcard.2006.03.002.
3. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation. 2011;123:551-565. doi: 10.1161/CIRCULATIONAHA.109.912568.
4. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241:507-532. doi: 10.1016/j.atherosclerosis.2015.05.007.
5. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110:624-637. doi: 10.1161/CIRCRESAHA.111.243386.
6. Fadini GP, Baesso I, Albiero M, Sartore S, Agostini C, Avogaro A. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis. 2008;197:496-503. doi: 10.1016/j. atherosclerosis.2007.12.039.
7. Asahara T, Kawamoto A, Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells. 2011;29:1650-1655. doi: 10.1002/stem.745.
8. Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis. 2007;194:46-54. doi: 10.1016/j.atherosclerosis.2007.03.046.
9. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434-438. doi: 10.1038/7434.
10. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood. 2005;106:1525-1531. doi: 10.1182/blood-2005-04-1509.
11. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://handbook.cochrane.org.
12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
13. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216. doi: 10.1371/ journal.pmed.1001216.
14. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
15. Viechtbauer W, Cheung MW. Outlier and influence diagnostics for metaanalysis. Res Synth Methods. 2010;1:112-125. doi: 10.1002/jrsm.11.
16. Alba AC, Lalonde SD, Rao V, Walter SD, Guyatt GH, Ross HJ. Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study. Can J Cardiol. 2013;29:1657-1664. doi: 10.1016/j.cjca.2013.06.010.
17. Bonello L, Harhouri K, Baumstarck K, Arnaud L, Lesavre N, Piot C, Paganelli F, Dignat-George F, Sabatier F. Mobilization of CD34+ KDR+ endothelial progenitor cells predicts target lesion revascularization. J Thromb Haemost. 2012;10:1906-1913. doi: 10.1111/j.1538-7836.2012.04854.x.
18. Briguori C, Testa U, Riccioni R, Colombo A, Petrucci E, Condorelli G, Mariani G, D'Andrea D, De Micco F, Rivera NV, Puca AA, Peschle C, Condorelli G. Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB J. 2010;24:1981-1988. doi: 10.1096/fj.09-138198.
19. Chiang CH, Huang PH, Chiu CC, Hsu CY, Leu HB, Huang CC, Chen JW, Lin SJ. Reduction of circulating endothelial progenitor cell level is associated with contrast-induced nephropathy in patients undergoing percutaneous coronary and peripheral interventions. PLoS One. 2014;9:e89942. doi: 10.1371/journal.pone.0089942.
20. Cuadrado-Godia E, Regueiro A, Nunez J, Diaz-Ricard M, Novella S, Oliveras A, Valverde MA, Marrugat J, Ois A, Giralt-Steinhauer E, Sanchis J, Escolar G, Hermenegildo C, Heras M, Roquer J. Endothelial progenitor cells predict cardiovascular events after atherothrombotic stroke and acute myocardial infarction. A PROCELL Substudy. PLoS One. 2015;10:e0132415. doi: 10.1371/journal.pone.0132415.
21. Fadini GP, de Kreutzenberg S, Agostini C, Boscaro E, Tiengo A, Dimmeler S, Avogaro A. Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis. 2009;207:213-219. doi: 10.1016/j.atherosclerosis.2009.03.040.
22. Haine SE, Van Craenenbroeck EM, Hoymans VY, Miljoen HP, Vandendriessche TR, Claeys MJ, Frederix G, Conraads VM, Bosmans JM, Vrints CJ. Levels of circulating CD34+/KDR+ cells do not predict coronary in-stent restenosis. Can J Cardiol. 2014;30:102-108. doi: 10.1016/j.cjca.2013.10.012.
23. Lee HJ, Kim W, Kim WS, Woo JS, Kim YG, Moon JY, Lee SH, Ihm CG, Lee TW, Jeong KH. Circulating endothelial progenitor cell levels predict cardiovascular events in end-stage renal disease patients on maintenance hemodialysis. Nephron. 2015;130:151-158. doi: 10.1159/000430471.
24. Lorenzen J, David S, Bahlmann FH, de Groot K, Bahlmann E, Kielstein JT, Haller H, Fliser D. Endothelial progenitor cells and cardiovascular events in patients with chronic kidney disease - a prospective follow-up study. PLoS One. 2010;5:e11477. doi: 10.1371/journal.pone.0011477.
25. Marti-Fabregas J, Delgado-Mederos R, Crespo J, Pena E, Marin R, Jimenez-Xarrie E, Fernandez-Arcos A, Perez-Perez J, Martinez-Domeno A, Camps-Renom P, Prats-Sanchez L, Casoni F, Badimon L. Circulating endothelial progenitor cells and the risk of vascular events after ischemic stroke. PLoS One. 2015;10:e0124895. doi: 10.1371/journal.pone.0124895.
26. Maruyama S, Taguchi A, Iwashima S, et al. Low circulating CD34+ cell count is associated with poor prognosis in chronic hemodialysis patients. Kidney Int. 2008;74:1603-1609. doi: 10.1038/ki.2008.495.
27. Padfield GJ, Tura-Ceide O, Freyer E, Barclay GR, Turner M, Newby DE, Mills NL. Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease. Heart. 2013;99:791-798. doi: 10.1136/heartjnl-2012-302949.
28. Patel RS, Li Q, Ghasemzadeh N, et al. Circulating CD34+ progenitor cells and risk of mortality in a population with coronary artery disease. Circ Res. 2015;116:289-297. doi: 10.1161/CIRCRESAHA.116.304187.
29. Pelliccia F, Pasceri V, Rosano G, Pristipino C, Roncella A, Speciale G, Pannarale G, Schiariti M, Greco C, Gaudio C. Endothelial progenitor cells predict long-term prognosis in patients with stable angina treated with percutaneous coronary intervention: five-year follow-up of the PROCREATION study. Circ J. 2013;77:1728-1735.
30. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111:2981-2987. doi: 10.1161/CIRCULATIONAHA.104.504340.
31. Schober A, Hoffmann R, Opree N, Knarren S, Iofina E, Hutschenreuter G, Hanrath P, Weber C. Peripheral CD34+ cells and the risk of instent restenosis in patients with coronary heart disease. Am J Cardiol. 2005;96:1116-1122. doi: 10.1016/j.amjcard.2005.06.042.
32. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007. doi: 10.1056/NEJMoa043814.
33. Wu CC, Huang PH, Lai CL, Leu HB, Chen JW, Lin SJ. The impact of endothelial progenitor cells on restenosis after percutaneous angioplasty of hemodialysis vascular access. PLoS One. 2014;9:e101058. doi: 10.1371/ journal.pone.0101058.
34. Yu CW, Choi SC, Hong SJ, Choi JH, Park CY, Kim JH, Park JH, Ahn CM, Lim DS. Cardiovascular event rates in patients with ST-elevation myocardial infarction were lower with early increases in mobilization of Oct4(high)Nanog(high) stem cells into the peripheral circulation during a 4-year follow-up. Int J Cardiol. 2013;168:2533-2539. doi: 10.1016/j. ijcard.2013.03.060.
35. Lu CL, Leu JG, Liu WC, Zheng CM, Lin YF, Shyu JF, Wu CC, Lu KC. Endothelial progenitor cells predict long-term mortality in hemodialysis patients. Int J Med Sci. 2016;13:240-247. doi: 10.7150/ijms.14209.
36. Shimoni S, Bar I, Meledin V, Derazne E, Gandelman G, George J. Circulating endothelial progenitor cells and clinical outcome in patients with aortic stenosis. PLoS One. 2016;11:e0148766. doi:10.1371/journal. pone.0148766.
37. Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S, Lombardi M, Galiuto L, Liuzzo G, Andreotti F, Lanza GA, Contemi AM, Leone G, Crea F. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005;26:1196-1204. doi: 10.1093/eurheartj/ehi164.
38. Wyderka R, Wojakowski W, Jadczyk T, Maślankiewicz K, Parma Z, Pawłowski T, Musiałek P, Majka M, Krol M, Kuczmik W, Dworowy S, Korzeniowska B, Ratajczak MZ, Tendera M. Mobilization of CD34+CXCR4+ stem/progenitor cells and the parameters of left ventricular function and remodeling in 1-year follow-up of patients with acute myocardial infarction. Mediators Inflamm. 2012;2012:564027. doi: 10.1155/2012/564027.
39. Grąbczewska Z, Dȩbski R, Goralczyk K, Świątkiewicz I, Kubica J. Does mobilisation of CD34+ stem cells along with VEGF, angiogenin, IL-6, IL-8, and hsCRP levels allow predicting the direction of left ventricular ejection fraction and wall motion score index changes in patients with myocardial infarction? Kardiol Pol. 2013;71:464-471. doi: 10.5603/KP.2013.0092.
40. Jeong HS, Hong SJ, Park JH, Kim JH, Choi SC, Ahn CM, Kim JS, Lim DS. Correlation between circulating angiogenic cell mobilizations and recovery of coronary flow reserve in patients with acute myocardial infarction. Circ J. 2012;76:1213-1221.
41. Wojakowski W, Pyrlik A, Krol M, Buszman P, Ochała A, Milewski K, Smolka G, Kawecki D, Rudnik A, Pawłowski T, Jadczyk T, Wyderka R, Cybulski W, Dworowy S, Tendera M. Circulating endothelial progenitor cells are inversely correlated with in-stent restenosis in patients with non-ST-segment elevation acute coronary syndromes treated with EPC-capture stents (JACK-EPC trial). Minerva Cardioangiol. 2013;61:301-311.
42. De Maria GL, Porto I, Burzotta F, Brancati MF, Trani C, Pirozzolo G, Leone AM, Niccoli G, Prati F, Crea F. Dual role of circulating endothelial progenitor cells in stent struts endothelialisation and neointimal regrowth: a substudy of the IN-PACT CORO trial. Cardiovasc Revasc Med. 2015;16:20-26. doi: 10.1016/j.carrev.2014.10.008.
43. Tsai NW, Hung SH, Huang CR, Chang HW, Chang WN, Lee LH, Wang HC, Lin YJ, Lin WC, Cheng BC, Chiang YF, Su YJ, Tsai TR, Lu CH. The association between circulating endothelial progenitor cells and outcome in different subtypes of acute ischemic stroke. Clin Chim Acta. 2014;427:6-10. doi: 10.1016/j.cca.2013.09.029.
44. Fadini GP. A look at the bone marrow predicts the global outcome. Circ Res. 2015;116:232-234. doi: 10.1161/CIRCRESAHA.114.305501.
45. Fadini GP, Albiero M, Seeger F, Poncina N, Menegazzo L, Angelini A, Castellani C, Thiene G, Agostini C, Cappellari R, Boscaro E, Zeiher A, Dimmeler S, Avogaro A. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic Res Cardiol. 2013;108:313. doi: 10.1007/ s00395-012-0313-1.
46. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5:213-226. doi: 10.1089/scd.1.1996.5.213.
47. Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood. 2014;124:2775-2783. doi: 10.1182/blood-2014-05-526285.
48. Fadini GP, Maruyama S, Ozaki T, Taguchi A, Meigs J, Dimmeler S, Zeiher AM, de Kreutzenberg S, Avogaro A, Nickenig G, Schmidt-Lucke C, Werner N. Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One. 2010;5:e11488. doi: 10.1371/ journal.pone.0011488.
49. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116. doi: 10.1056/NEJMoa0707064.